News

An ancient rock art near Aswan may show one of Egypt’s earliest rulers, revealing new clues about the birth of state power.
The University of Arkansas is recognizing students for making the spring 2025 Chancellor’s List. To qualify for the ...
Scholar Rock to Present Comprehensive Update at 2025 Annual Cure SMA Research and Clinical Care Meeting, Including Positive Results from Pivotal Phase 3 SAPPHIRE Trial ...
Shares of Scholar Rock Holdings (SRRK) jumped nearly 15% in intraday trading Wednesday after the biopharmaceutical firm reported positive results from a weight-loss drug trial. The Cambridge, ...
Scholar Rock, a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for patients with spinal muscular atrophy and additional severe and debilitating ...
Shares of Scholar Rock Holding (NASDAQ: SRRK) are soaring today, up 13.7% as of 1:14 p.m. ET. The move comes as the S&P 500 and Nasdaq Composite were up modestly. Scholar Rock, a biopharma company ...
Scholar Rock Reports First Quarter 2025 Financial Results and Highlights Business Progress Apitegromab BLA accepted under priority review for patients with Spinal Muscular Atrophy (SMA) and FDA ...
Although there are many examples throughout history of positive changes in top company management teams, important personnel moves tend to unsettle investors. Scholar Rock's C-suite now looks ...
Biotech stock Scholar Rock (SRRK -1.28%) was popular among investors on Wednesday after a positive new analyst note on the company made the rounds.
Scholar Rock Holding Corporation's apitegromab shows promise for SMA treatment, aims for 2025 launch. Click for my updated look at SRRK stock and why I'm upgrading.
I analyze Scholar Rock's promising Phase 3 results for SMA drug, but warn of financial challenges and recommend a Hold rating. Read more here.